US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Odyssey Therapeutics, Inc. - Common Stock (NQ:ODTX)

19.60 +0.52 (+2.73%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Odyssey Therapeutics, Inc. - Common Stock

News headline image
Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts ↗
Odyssey Therapeutics (NASDAQ:ODTX) presented additional data from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative colitis, during its UEG... 
Via MarketBeat
News headline image
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
From Odyssey Therapeutics Inc
Via GlobeNewswire
News headline image
Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
Topline induction results expected in the second half of 2027 
From Odyssey Therapeutics Inc
Via GlobeNewswire
News headline image
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
From Odyssey Therapeutics Inc
Via GlobeNewswire
News headline image
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
From Odyssey Therapeutics Inc
Via GlobeNewswire
News headline image
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
From Odyssey Therapeutics Inc
Via GlobeNewswire
News headline image
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Odyssey Therapeutics Inc
Via GlobeNewswire
News headline image
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Odyssey Therapeutics Inc
Via GlobeNewswire